The Technical AnalystExchange: PNK Industry: Biotechnology
Burzynski Research Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0428
America/New_York / 25 apr 2024 @ 10:47
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 5.62 mill |
| EPS: | -0.0100 |
| P/E: | -4.28 |
| Earnings Date: | May 30, 2023 |
| SharesOutstanding: | 131.45 mill |
| Avg Daily Volume: | 0.0030 mill |
| RATING 2024-04-25 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.28 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -4.28 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0000 (-99.98%) $-0.0427 |
| Date: 2024-05-01 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0388 - 0.0468 ( +/- 9.36%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0428 (0.00% ) |
| Volume | 0.0024 mill |
| Avg. Vol. | 0.0030 mill |
| % of Avg. Vol | 79.64 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BZYR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BZYR
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs to treat cancer. The company is also involved in the production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. Burzynski Research Institute, Inc. was founded in 1977 and is based in Houston, Texas.